Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 11/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.84 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 1/20 | 0.34 |
| ▸ | FURIN | P09958 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 3/20 | 0.34 |
| ▸ | FLT3 | P36888 | 3/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.34 |
| ▸ | MERTK | Q12866 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21550842 | 1.00 | SLC16A3 (1.00) | SLC16A3KCNH2AKT1AKT2FURIN | |
| SCHEMBL21550454 | 0.97 | SLC16A3 (0.94) | SLC16A3KCNH2FURINAXLFLT3 | |
| SCHEMBL21550457 | 0.97 | SLC16A3 (0.94) | SLC16A3KCNH2FURINAXLFLT3 | |
| SCHEMBL23116316 | 0.94 | SLC16A3 (0.88) | SLC16A3KCNH2AKT1AKT2LMNA | |
| SCHEMBL21565652 | 0.94 | SLC16A3 (0.88) | SLC16A3KCNH2AKT1AKT2LMNA | |
| SCHEMBL21550761 | 0.94 | SLC16A3 (0.88) | SLC16A3KCNH2AKT1AKT2 | |
| SCHEMBL21550762 | 0.94 | SLC16A3 (0.88) | SLC16A3KCNH2AKT1AKT2 | |
| SCHEMBL21565729 | 0.93 | SLC16A3 (0.87) | SLC16A3KCNH2AKT1AKT2FURIN | |
| SCHEMBL21565725 | 0.93 | SLC16A3 (0.87) | SLC16A3KCNH2AKT1AKT2 | |
| SCHEMBL23116274 | 0.92 | SLC16A3 (0.85) | SLC16A3KCNH2AXLFLT3TYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851432-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-12-26 | — | — | US | claimed |
| EP-3790879-B1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-06-29 | — | — | EP | claimed |
| US-20210340150-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-11-04 | — | — | US | claimed |
| US-11084827-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-08-10 | — | — | US | claimed |
| US-20210087196-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-03-25 | — | — | US | claimed |
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-11851432-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-12-26 | — | — | US | disclosed |
| EP-4134368-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-15 | — | — | EP | disclosed |
| EP-3790879-B1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-06-29 | — | — | EP | disclosed |
| US-20210340150-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-11-04 | — | — | US | disclosed |
| US-11084827-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20210087196-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3790879-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019215316-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | SLC16A3 3/4885KCNH2 410/4885AKT1 3241/4885 |
| US-11084827-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | SLC16A3 3/4885KCNH2 410/4885AKT1 3241/4885 |
| US-20210087196-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ABCC4, ABCB1, SLC16A3 | SLC16A3 3/4885KCNH2 410/4885AKT1 3241/4885 |
| US-20210340150-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ABCC4, ABCB1, SLC16A3 | SLC16A3 3/4885KCNH2 410/4885AKT1 3241/4885 |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ABCC4, ABCB1, SLC16A3 | SLC16A3 3/4885KCNH2 410/4885AKT1 3241/4885 |
| US-11851432-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | SLC16A3 3/4885KCNH2 410/4885AKT1 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.